"rationale","label","instanceType","name","uuid:ID","description","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign","Study Design 1","81253848-ce1c-4719-964c-c63675fba12f","The main design for the study","StudyDesign_1"
